• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Brain Potentials Fail to Reliably Track Opioid Analgesia During Anesthesia

by
November 19, 2026
in Health
Reading Time: 6 mins read
0
Brain Potentials Fail to Reliably Track Opioid Analgesia During Anesthesia

Brain Potentials Fail to Reliably Track Opioid Analgesia During Anesthesia

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Contact heat evoked potentials fail to serve as a reliable, direct clinical monitor of opioid-mediated analgesia during general anesthesia, according to a prospective randomized patient investigation published in the Journal of Clinical Monitoring and Computing. The clinical trial, conducted by an anesthesia research team across adult surgical patients receiving graded infusions of the short-acting opioid remifentanil, revealed that electroencephalographic wave amplitudes elicited by calibrated thermal skin stimulation did not correlate with changes in subjective pain ratings. Although administration of the synthetic opioid significantly depressed contact heat evoked potential amplitudes compared to unmedicated baseline recordings, the observed signal reduction failed to differentiate between distinct drug dosages or track the degree of patient-reported analgesia. Furthermore, the complete abolishment of these evoked electrophysiological responses upon the pharmacological induction of unconsciousness demonstrates that cortical heat potentials cannot fulfill the longstanding search for an objective real-time monitor of intraoperative antinociception during clinical surgery.

While the hypnotic state of the brain is routinely tracked using processed electroencephalography and muscle paralysis is quantitatively titrated with acceleromyography, clinical anesthesiology has lacked an equivalent, direct method for measuring antinociceptive drug actions on the central nervous system. When noxious surgical stimulation remains unchecked by adequate analgesia, patients face increased risks of catabolism, systemic immunosuppression, cognitive impairment, and severe postoperative pain.

Under normal neurophysiological conditions, noxious stimulation and tissue injury trigger local chemical mediators such as prostaglandins that activate peripheral unmyelinated C and finely myelinated A-delta primary afferent nerve fibers. These ascending impulses travel along the axon into the dorsal horn of the spinal cord, where neurotransmitters such as substance P propagate the nociceptive signal across second-order neurons toward the thalamus via the spinothalamic, spinoreticular, and spinomesencephalic tracts. From the thalamic relay centers, third-order neurons project to widespread regions across the somatosensory cortex, limbic structures, and frontal lobes, connecting sensory, cognitive, and affective processing to generate the conscious experience of pain. In parallel, descending inhibitory pathways descending through the midbrain and medulla oblongata release endogenous opioids to suppress substance P transmission at the dorsal horn. Even under general anesthesia, noxious surgical signals still reach the brain, making direct monitoring essential to suppress adverse physiological cascades.

To overcome the known vulnerabilities of autonomic surrogate monitors, researchers have explored electrophysiological signals recorded from the human electroencephalogram in response to standardized sensory stimulation. Evoked potentials reflect the functional integrity and dynamic processing of peripheral and central neural pathways throughout the nervous system, characterized by measurable latency delays and microvolt amplitude deflections. In particular, contact heat evoked potentials elicited by specialized contact thermodes have emerged as promising candidates because they directly represent cortical responsiveness following noxious thermal stimulation, correlate with conscious pain intensity in waking subjects, and remain largely independent of cardiovascular confounders. Prior pilot work had indicated that remifentanil could dose-dependently attenuate contact heat evoked potential amplitudes in human subjects without producing global cortical suppression. Consequently, investigators hypothesized that tracking the peak-to-peak amplitude between the initial positive P1 and negative N2 waveforms could provide an objective, real-time gauge of opioid-mediated analgesia during clinical procedures.

To rigorously test this hypothesis under standardized clinical conditions, researchers designed a prospective randomized investigation approved by the ethics committee of Witten/Herdecke University in Germany and registered under the German Clinical Trials Register. The research protocol recruited one hundred and twenty adult patients aged eighteen to fifty years who were classified as American Society of Anesthesiologists physical status class one or two and scheduled for elective surgical operations. The surgical cohort primarily underwent thyroid procedures, followed by orthopedic joint and ligament reconstructions, trauma interventions, spinal operations, and other general surgical interventions. Eleven initial participants were excluded during the trial due to heat pain intolerance, loss of responsiveness at baseline, missing recording triggers, opioid-induced thoracic rigidity, or protocol violations. Following approved replacement recruitment, the final analytical cohort consisted of one hundred and nineteen patients randomized into four distinct remifentanil infusion regimens delivering 0.05, 0.1, 0.2, or 0.4 micrograms per kilogram per minute.

The investigation evaluated patients across three structured experimental phases to capture neurophysiological and subjective responses under precise pharmacological control. The initial phase, designated T0, recorded baseline electroencephalographic signals, pain thresholds, and clinical sedation without medication. The second phase, designated T1, administered group-specific remifentanil infusions, beginning recordings after a ten-minute equilibration period. The final phase, designated T2, administered intravenous propofol boluses until patients lost responsiveness to verbal commands, maintaining general anesthesia with State and Response Entropy values between forty and sixty. Calibrated thermal stimuli were delivered to the volar forearm using an advanced contact heat sensory evaluation system. Individual heat pain thresholds were determined before drug administration by increasing temperatures in one-degree Celsius increments, avoiding reaction-time errors. This threshold, rated as ten on a visual analog scale, exhibited a median value of fifty-three degrees Celsius, with subsequent experimental testing performed twenty percent above each patient’s individual threshold across four thirty-stimulus sequences.

To avoid neural habituation and prevent tissue erythema, the thermode delivered stimuli at intervals of eight seconds with ten percent temporal jitter, interspersed with five-minute rest periods between sequences and slight positional adjustments every five pulses. High-resolution electroencephalographic signals were captured from eight active surface electrodes positioned across frontal, temporal, parietal, and occipital scalp regions, recorded at a five-kilohertz sampling rate. Following bandpass filtering between 0.3 and 30 hertz, contact heat evoked potentials were averaged across one hundred and twenty sweeps over a 2048-millisecond analysis window to extract P1-N2 peak-to-peak amplitudes. Sedation was tracked clinically using the five-point Observer’s Assessment of Alertness and Sedation scale, and electrophysiologically via middle latency auditory evoked potentials. Auditory stimuli consisted of one thousand click sounds delivered at seventy decibels above hearing thresholds at 8.3 hertz through in-ear speakers, with Pa and Nb waveform peaks analyzed after bandpass filtering between 26 and 400 hertz.

The experimental results demonstrated that remifentanil produced expected, dose-dependent reductions in subjective pain ratings across the studied cohorts. Median visual analog scale scores decreased markedly from the baseline score of ten down to values between one and six during remifentanil infusion, with the highest dosage tier achieving significantly lower pain scores than lower tiers. Non-parametric testing confirmed a significant monotonic downward trend across dosages, supported by a strong inverse correlation between remifentanil dose and visual analog scale scores. Electrophysiological analysis revealed that P1-N2 peak-to-peak amplitudes significantly decreased from baseline to the remifentanil phase within all four dosage cohorts. However, the relative amplitude reductions between baseline and drug infusion showed no statistically significant differences across the four dosing groups. Although researchers detected a modest positive correlation between remifentanil dosage and contact heat amplitudes, the electrophysiological signal failed to discriminate between different drug infusion rates, indicating a dose-independent suppressive effect.

Crucially, the primary clinical endpoint revealed no meaningful correlation between subjective pain perception and contact heat evoked potential amplitudes. Visual analog scale ratings showed no statistically significant correlation with absolute P1-N2 amplitudes during remifentanil infusion or with relative amplitude reductions from baseline measurements. Clinical applicability was further compromised by substantial waveform inconsistency and recording failures across the study population. Contact heat evoked potentials could not be detected in eleven patients at baseline, and an additional five participants lost detectable waveforms during remifentanil administration despite experiencing intact pain perception. Moreover, approximately thirty percent of the evaluated patients paradoxically exhibited increased rather than decreased evoked wave amplitudes during opioid administration compared to baseline. Investigators attributed these paradoxical increases to lower signal quality and agitation-induced motion artifacts during initial waking measurements, which degraded baseline signal-to-noise ratios and potentially led blinded analysts to misinterpret low-amplitude noise spikes as genuine physiological waveforms.

Sedative side effects introduced another major confounding factor, as remifentanil produced clear dose-dependent sedation evidenced by declining alertness scores and prolonged auditory evoked potential Pa and Nb wave latencies. This concomitant sedation inevitably blunts conscious cortical sensory processing, obscuring whether waveform attenuation stemmed from true antinociception or general central depression. Most decisively, contact heat evoked potentials vanished entirely following propofol-induced loss of responsiveness, as synergistic anesthetic interactions completely abolished detectable cortical potentials under surgical depths of general anesthesia. Gender comparisons also revealed significant physiological divergence, with female participants exhibiting higher baseline amplitudes, greater amplitude reductions, and lower pain scores than males. Ultimately, the authors concluded that contact heat evoked potential monitoring is unsuitable for the direct assessment of analgesia during general anesthesia, highlighting that objective nociception tracking remains an unresolved challenge requiring novel physiological approaches.

Subject of Research: Evaluation of contact heat evoked potentials for measuring intraoperative analgesia

Article Title: Contact heat evoked potentials as a measure of the analgesic component of anesthesia – a patient study

Article References: Zanner, R., Untergehrer, G., Jordan, D., Kreuzer, M., & Schneider, G. (2026). Contact heat evoked potentials as a measure of the analgesic component of anesthesia – a patient study. Journal of Clinical Monitoring and Computing. https://doi.org/10.1007/s10877-026-01501-4

Image Credits: AI Generated

DOI: 10.1007/s10877-026-01501-4

Keywords: contact heat evoked potentials, remifentanil, propofol, general anesthesia, nociception monitoring, P1-N2 amplitude, visual analog scale, intraoperative analgesia, auditory evoked potentials, Observer's Assessment of Alertness/Sedation, loss of responsiveness, A-delta fibers, C fibers, substance P, electroencephalography, thermal pain threshold, middle latency auditory evoked potentials, spectral entropy

News Source: Cassandra Pierce. (November 19, 2026). Brain Potentials Fail to Reliably Track Opioid Analgesia During Anesthesia. Scienmag.

Tags: A-delta fibersauditory evoked potentialsC fiberscontact heat evoked potentialselectroencephalographygeneral anesthesiaintraoperative analgesialoss of responsivenessmiddle latency auditory evoked potentialsnociception monitoringObserver's Assessment of Alertness/SedationP1-N2 amplitudePropofolremifentanilspectral entropysubstance Pthermal pain thresholdvisual analog scale
Share12Tweet7Share2ShareShareShare1

Related Posts

Compounding Discrimination and Isolation Burden Diverse LGBTQIA+ Dementia Caregivers

Compounding Discrimination and Isolation Burden Diverse LGBTQIA+ Dementia Caregivers

November 19, 2026
Inertial Sensors Show Limited Reliability for Parkinson Motor Scoring in Meta-Analysis

Inertial Sensors Show Limited Reliability for Parkinson Motor Scoring in Meta-Analysis

November 19, 2026

Reactive Astrogliosis Relates to Worse Visual Memory in Non-Demented Older Adults

November 19, 2026

Ultra-Low-Dose Cone-Beam CT Effectively Facilitates Cleft Craniofacial Surgery Planning

November 19, 2026

POPULAR NEWS

  • Virtual Reality Cycling Proves Feasible and Potentially Safe in ICU Pilot

    Virtual Reality Cycling Proves Feasible and Potentially Safe in ICU Pilot

    29 shares
    Share 12 Tweet 7
  • Clinical Documentation and Imaging Practices for Positional Vertigo Vary After Implementation

    29 shares
    Share 12 Tweet 7
  • Green Tea Compound Boosts Irinotecan Efficacy and Curbs Angiogenesis in Mice

    29 shares
    Share 12 Tweet 7
  • Gradual Dexamethasone Dose Reduction Manages Chemotherapy-Related Delirium in Lung Cancer Patients

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Compounding Discrimination and Isolation Burden Diverse LGBTQIA+ Dementia Caregivers

Hybrid Algorithm Optimizes Heterogeneous Barge Scheduling Under Maritime Transshipment Uncertainty

New Hairless Mouse Model Enhances Precision in Non-Invasive Cancer Imaging

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.